Physician profile
Yousef Elyaman
NPI 1548248446
$896.78
in general payments reported to CMS, 2019-2025
19 companies · $94.47 in 2025
The $94.47 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.90 · 2020: $225 · 2021: $121 · 2022: $123 · 2023: $161 · 2024: $135 · 2025: $94.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $255.18 | 2020-2022 | |
| Exact Sciences Corporation | $158.94 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $76.00 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $57.51 | 2020-2025 | Arexvy, Shingrix, Penmenvy |
| Abbvie INC. | $51.39 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $43.92 | 2022-2023 | Contrave |
| Averitas Pharma INC. | $41.10 | 2024 | Qutenza |
| Amgen INC. | $30.86 | 2019-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $27.26 | 2025 | Veozah |
| Philips North America LLC | $22.55 | 2020 | |
| Indivior INC. | $17.46 | 2022 | |
| Pfizer INC. | $17.21 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.08 | 2022 | |
| Abbott Laboratories | $16.05 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.08 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $13.76 | 2019 | |
| Bardy Diagnostics, INC. | $13.50 | 2021 | |
| Genentech USA, INC. | $12.39 | 2019 | |
| Eisai INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousef Elyaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.